Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors.
Phase of Trial: Phase I/II
Latest Information Update: 26 May 2017
At a glance
- Drugs BNC 105 (Primary) ; Everolimus
- Indications Renal cancer; Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms DisrupTOR-1
- 17 Apr 2017 Status changed from active, no longer recruiting to completed.
- 14 Nov 2016 Planned End Date changed from 1 Oct 2016 to 1 Nov 2016.
- 14 Nov 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Nov 2016.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History